Diagnostic Overlap Between CP/CPPS and IC/BPS

The American Urological Association (AUA) guidelines state that chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) and interstitial cystitis/bladder pain syndrome (IC/BPS) present with nearly identical symptoms in men—suprapubic pain, incomplete bladder emptying, and urinary frequency—so IC/BPS should be strongly considered when bladder‑related pain is reported, and many men meet criteria for both conditions. 1
When clinical features of CP/CPPS and IC/BPS overlap, the treatment plan should incorporate therapies directed at both disorders rather than selecting one pathway exclusively. 2
Realistic expectations are essential: no single therapy reliably benefits the majority of patients, and multiple therapeutic options often must be trialed before satisfactory symptom control is achieved. 1

First‑Line Behavioral and Physical Interventions

Initiate pelvic‑floor physical therapy using manual techniques (myofascial trigger‑point release and internal pelvic‑floor manipulation) performed by a specially trained therapist as the initial management step for men with CP/CPPS. 1
Advise patients to eliminate common bladder irritants (caffeinated beverages, citrus, spicy foods, and alcohol) and to follow a systematic elimination diet to identify personal triggers. 3
Recommend restricting fluid intake in the evening to lessen nocturnal urinary symptoms while maintaining adequate daytime hydration to dilute urinary irritants. 3
Apply local heat or cold to the suprapubic region or perineum for temporary pain relief. 4
Incorporate stress‑management strategies such as meditation and progressive muscle relaxation to address the psychosocial component of chronic pelvic pain. 4

Amitriptyline starting at 10 mg daily and titrated up to 100 mg as tolerated provides pain relief with Grade B evidence, although adverse effects are common. 3
Hydroxyzine is an alternative second‑line oral agent with Grade B/C evidence and a favorable side‑effect profile. 4

Cimetidine improves nocturia and bladder‑related symptoms with Grade B evidence and no reported adverse events. 3
Pentosan polysulfate sodium (Elmiron) is FDA‑approved for IC/BPS; however, mandatory ophthalmologic monitoring is required because of a risk of macular damage. 4

Therapy	Mechanism / Benefit	Evidence Grade
Heparin intravesical instillation	Restores the glycosaminoglycan (GAG) layer of the bladder urothelium, leading to clinically significant symptom improvement.	Not formally graded (Praxis)
Lidocaine intravesical instillation	Provides rapid‑onset, temporary relief of bladder pain.	Not formally graded (Praxis)

Throughout all treatment phases, adopt a multimodal pain‑management strategy that strongly prefers non‑opioid alternatives given the chronic nature of CP/CPPS. 3
Pain management alone is insufficient; underlying bladder and pelvic‑floor dysfunction must be concurrently addressed. 4

Sacral neuromodulation may be considered when conventional therapies fail to achieve adequate symptom control. 4

Document baseline symptom severity using a validated instrument such as the NIH Chronic Prostatitis Symptom Index (NIH‑CPSI) to enable objective assessment of treatment response. 4
Perform cystoscopy in patients with persistent symptoms to identify Hunner lesions, which indicate IC/BPS and guide targeted interventions (e.g., fulguration or triamcinolone injection). Evidence from the Journal of Urology supports this diagnostic step. 5

The American Urological Association (AUA) includes quercetin among first‑line over‑the‑counter (OTC) products for behavioral management of interstitial cystitis/bladder pain syndrome (IC/BPS), a condition with symptoms nearly identical to CPPS in men. 6
Within the AUA guideline, quercetin is listed together with calcium glycerophosphates and pyridium as OTC agents that patients commonly start themselves for symptom relief. 7
The AUA acknowledges that the existing literature on quercetin is limited, but notes that individual patients may experience worthwhile symptom alleviation. 6
This recommendation is classified as a Clinical Principle, indicating it is based on clinical experience rather than high‑quality trial evidence. 6

Quercetin may be offered as a first‑line OTC supplement for CPPS, especially when bladder‑related or organ‑specific pain predominates; however, the evidence base is modest and patient response is unpredictable. 7
The AUA advises against routine Kegel exercises in CPPS patients because they can exacerbate pelvic‑floor hypertonicity. 8

After lateral sphincterotomy (or similar pelvic‑floor surgery), wound‑related complications such as fistula, bleeding, or abscess occur in up to 3 % of cases. 9
Incontinence following these procedures can be temporary in up to 30 % of patients and permanent in about 10 %, potentially contributing to ongoing pelvic‑floor dysfunction. 10